Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
11
×
eli lilly
11
×
life sciences
national blog main
11
×
fda
indiana blog main
indiana top stories
biotech
boston blog main
clinical trials
national
national top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
allergan
deals
novartis
startups
teva pharmaceutical
abbvie
astrazeneca
biogen
bristol-myers squibb
What
drug
fda
bio
migraine
new
roundup
won
approval
class
drugs
eli
medicines
approved
buy
days
decades
developed
giant
lilly
nod
pain
pharmaceutical
starts
wins
acquisitions
acute
addresses
administration
adults
allergan
alliance
alzheimer’s
amgen
angry
announced
anti
appetite
arguments
august
benefited
Language
unset
Current search:
amgen
×
" national blog main "
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines